Clinical trials: Alzheimer's Dementia (AD)
Alzheimer Disease
Implantable Vagus Nerve Stimulation Modulation of Coeruleus-Norepinephrine Network for Mild-Moderate AD Patients
A randomized controlled clinical study will be conducted in Xuanwu Hospital of Capital Medical University. This study initially explore the effect of selective vagus nerve(C fiber) stimulation on mild-to-moderate AD patients, in…
- Trial name
- NCT05575271
- Testing
- Vagus Nerve Stimulation Modulation of the Coeruleus-Norepinephrine Network
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Xuanwu Hospital, Beijing
Subjective Cognitive Decline, Preclinical Alzheimer's Disease
Prediction of Cognitive Decline by Neuroimaging Techniques and the Application in Diagnosis and Treatment of Preclinical AD
This study is affiliated to Sino Longitudinal Study on Cognitive Decline, SILCODE. To establish models of normal and pathological cognitive aging.To collect the longitudinal data of SCD population, to study the dynamic changes of…
- Trial name
- NCT03370744
- Testing
- Neuropsychological scale
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- XuanwuH 2
AD - Alzheimer's Disease, MCI
A Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy
This is a non randomized, open-label Phase I study in Chinese participants. The goal of this clinical trial is to evaluate the safety and tolerability of a radioactive imaging agent called [18F]Flortaucipir Injection, which is…
- Trial name
- NCT07580703
- Testing
- [18F]Flortaucipir Injection
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Radiopharma
Mild Cognitive Impairment (MCI), Alzheimer Disease (AD)
Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers
Wellderly Brain is a randomized, direct-to-participant trial evaluating whether a virtually delivered, multidomain lifestyle coaching intervention can favorably impact plasma biomarkers of Alzheimer's disease (AD) in adults aged…
- Trial name
- WellderlyBrain (NCT07646054)
- Testing
- Education
- Where
- United States
- Volunteers
- 1,200 people
- Sponsor
- Scripps Translational Science Institute
Dementia, Alzheimer Dementia (AD)
Fuzhou Aging Brain Health Initiative
The goal of this observational study is to learn about the pathophysiological characterization and evolutionary patterns of Alzheimer's disease (AD) in older adults in Fujian Province, China.
- Conditions
- Dementia, Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
- Trial name
- FAITH (NCT07891429)
- Testing
- Fluids biomarker and neuroimaging of AD diagnosis
- Where
- 4 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Alzheimer's Disease
Improved Diagnosis of Alzheimer's Disease Using the Synchronous Neural Interaction™ Test
This study is designed to test the hypothesis that the Synchronous Neural Interaction™ Test is useful for diagnosing Probable Alzheimer's Disease according to standard criteria.
- Trial name
- NCT00666445
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Orasi Medical, Inc.
Alzheimer Disease
Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects
This is an investigator-initiated clinical (IIT)study.The main purpose of this study was to evaluate the diagnostic efficacy of XTR006 PET qualitative reading and quantitative analysis in detecting mild cognitive…
- Trial name
- NCT06151808
- Testing
- XTR006
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Mild Cognitive Impairment, Dementia
Implications for Management of PET Amyloid Classification Technology
The main purpose of this study is to explore the impact of an amyloid positron emission tomography and computed tomography (PET/CT) scan on physician diagnosis and management, including drug management and care practices, for…
- Conditions
- Mild Cognitive Impairment, Dementia, Alzheimer's Disease
- Trial name
- IMPACT (NCT02778971)
- Testing
- [18F]Flutemetamol
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Utah
Dementia, Mild, Depression
Decision Making Tool for Firearm Storage
This is a one-arm pilot study testing the feasibility and acceptability of a decision aid about safe firearm storage.
- Trial name
- NCT06382194
- Testing
- Decision aid
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
Effectiveness of Genistein in Mild Cognitive Impairment
Randomized, placebo-controlled, double-blind, multicenter clinical trial with two parallel study arms (experimental and placebo) to assess the efficacy of genistein extract consumption over 18 months on cognitive decline in…
- Trial name
- EXTRAGENIAL (NCT07385937)
- Testing
- Genistein
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Universidad Católica San Antonio de Murcia
Mild Cognitive Impairment, Dementia
Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial
The main purpose of this study is to build upon the evidence captured in the Imaging Dementia - Evidence for Amyloid Scanning (IDEAS; NCT02420756) trial to include valuable information regarding patient-reported outcomes and…
- Conditions
- Mild Cognitive Impairment, Dementia, Alzheimer's Disease
- Trial name
- IMPACT2 (NCT02781220)
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Utah
Alzheimer's Disease (AD)
Biomarkers in a Candian Memory Clinic
This is a prospective, observational, case control study in a real-world cohort of patients referred by a primary care physician to a tertiary memory clinic for cognitive concerns.
- Trial name
- BioMIND (NCT06843109)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Mild Cognitive Impairment, Alzheimer Disease (AD)
Microbiome in Aging of Gut and Brain
The Microbiome in Aging Gut and Brain (MiaGB) Study is an observational study designed to examine whether differences in the microorganisms living in the gut and mouth are associated with cognitive health and cognitive decline.
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease (AD), Dementia
- Trial name
- MiaGB (NCT07799402)
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Cognitive Dysfunction
Integrative Therapy for Holistic, Natural Cognition and Lifestyle Rehabilitation
An observational study to determine outcomes of older adults who are under naturopathic medical care for cognitive complaints at a specific clinic in Southern California.
- Trial name
- ITHNCLR (NCT04284449)
- Testing
- Whole-practice cognitive optimization
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- National University of Natural Medicine
Alzheimer Disease, Mild Cognitive Impairment
Orientation in AD Patients: PET-MR Study
Despite the high prevalence of Alzheimer's disease (AD), its underlying mechanisms remain poorly understood. An emerging body of evidence supports disorientation as an early marker for AD-related neurodegeneration.
- Trial name
- NCT03030365
- Testing
- Siemens "Biograph mMR" PET-MR (3T)
- Volunteers
- 30 people
- Sponsor
- Assuta Medical Center
Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI) Amnestic
Acoustic Stimulation During Sleep: Effects on Memory and p-tau217 in MCI
The goal of this clinical trial is to determine whether acoustic stimulation during sleep can enhance slow-wave sleep (SWS), improve cognitive function, and reduce AD-related pathology in individuals with mild cognitive…
- Conditions
- Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI) Amnestic, Cognitively Unimpaired
- Trial name
- PAS-MCI (NCT07529015)
- Testing
- Plase-Locked Acoustic Stimulation during slow-wave sleep
- Where
- Spain
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida)
Alzheimer's Disease, Mild Cognitive Impairment
Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)
The main purpose of this study is to assess the ability of a repeated high-frequency site-based computerized cognitive assessment to evaluate the potential treatment effects of donepezil (MK-0000) compared with placebo among…
- Trial name
- NCT04730635
- Testing
- Donepezil
- Where
- 10 sites in United States, Australia
- Volunteers
- 44 people
- Sponsor
- Merck Sharp & Dohme LLC
Early Alzheimers Disease, Mild Cognitive Impairment Due to AD
A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD
This is a phase 2B multicenter, randomized, double-blind, placebo-controlled, parallel group dose finding study to evaluate the safety, tolerability and efficacy of PQ912, an inhibitor of the glutaminyl cyclase enzyme, in 250…
- Trial name
- VIVIAD (NCT04498650)
- Testing
- PQ912
- Where
- 21 sites in Denmark, Germany and 3 more
- Volunteers
- 259 people
- Sponsor
- Vivoryon Therapeutics N.V.
Alzheimer's Disease
Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG)
The current study is intended to enrich and extend the database of Alzheimer's Disease (AD) and healthy control (HC) MEG scans and will include patients meeting DSM-IV-TR criteria for dementia of Alzheimer's type, and age- and…
- Trial name
- NCT00973518
- Where
- 2 sites in United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Orasi Medical, Inc.
Alzheimer Disease
To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia
The study is designed as a classic, randomized, double blind, placebo controlled, parallel group study including one active dose of PU AD and matching placebo, designed to assess safety, tolerability and pharmacological effects…
- Trial name
- NCT04311515
- Testing
- Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers
- Where
- 10 sites in United States
- Volunteers
- 4 people
- Sponsor
- Samus Therapeutics, Inc.